0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-31

IL-31

Brief Information

Name:Interleukin-31
Target Synonym:Interleukin 31,IL-31
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL1-H5247-SPR
 IL-31 SPR

Human IL-31, His Tag (Cat. No. IL1-H5247) immobilized on CM5 Chip can bind Human IL-31 RA, His Tag (Cat. No. ILA-H52H7) with an affinity constant of 52.1 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

IL1-H5247-SPR
 IL-31 SPR

Human IL-31, His Tag (Cat. No. IL1-H5247) capture on NTA-Series S sensor chip can bind Human IL-31 RA, Fc Tag (Cat. No. ILA-H5256) with an affinity constant of 37.1 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

IL-31,IL31,Interleukin-31

Background

IL-31 is an inflammatory cytokine that helps trigger cell-mediated immunity against pathogens. Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR. It has also been identified as a major player in a number of chronic inflammatory diseases, including atopic dermatitis. May function in skin immunity. IL-31 is produced by a variety of cells, namely type 2 helper (TH2) T-cells. IL-31 sends signals through a receptor complex made of IL-31RA and oncostatin M receptor β (OSMRβ) expressed in immune and epithelial cells. These signals activate three pathways: ERK1/2 MAP kinase, PI3K/AKT, and JAK1/2 signaling pathways.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NM26-2198 NM-26-2198 Phase 1 Clinical Kaken Pharmaceutical Co Ltd, Numab Therapeutics Ag Inflammation; Dermatitis, Atopic Details
NM26-2198 NM-26-2198 Phase 1 Clinical Kaken Pharmaceutical Co Ltd, Numab Therapeutics Ag Inflammation; Dermatitis, Atopic Details

This web search service is supported by Google Inc.

totop

Laisser un message